secwatch.observer — SEC 8-K summary
======================================

Issuer:     Penumbra Inc (PEN)
CIK:        0001321732
Form:       8-K
Filed at:   2026-07-30T20:14:23+00:00
Accession:  0001321732-26-000036
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Penumbra Q2 revenue $390M (+14.9% YoY); net income $34.8M; pending BSX acquisition
--------------------------------------------------------------------------------

- Revenue $390.0M, up 14.9% YoY; global thrombectomy $259.0M (+12.5%), embolization & access $131.1M (+20.0%).
- Gross profit margin 67.9%, up 1.9 percentage points YoY.
- Income from operations $41.0M; net income $34.8M.
- Operating expenses include $6.9M acquisition-related costs for pending Boston Scientific acquisition.
- Company will not provide FY2026 guidance due to pending acquisition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1321732/000132173226000036/0001321732-26-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1321732/000132173226000036/pen-20260730.htm
  HTML page:      https://secwatch.observer/filing/0001321732-26-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer